arrow
M

M. Lia Palomba

Memorial Sloan Kettering Cancer Center
H指数:39
被引数:1.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Phase I Study of Mogamulizumab in Combination with Pembrolizumab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma—A National Cancer Institute Experimental Therapeutics Clinical Trials Network (NCI-ETCTN) Trial

I期研究:Mogamulizumab联合Pembrolizumab治疗复发或难治性非霍奇金淋巴瘤患者——国家癌症研究所实验治疗临床研究网络(NCI-ETCTN)试验

Cancers
IF4.4
2026-01-170
OAAI
ANTIBODY TITERS OF VACCINE-PREVENTABLE PATHOGENS AT ONE YEAR POST CD19 CAR-T CELL THERAPY

疫苗可预防病原体的抗体滴度:CD19 CAR-T细胞治疗1年后

2025-11-010
PRE
Treatment outcomes and CNS relapse risk in patients with primary cutaneous DLBCL, leg-type in the rituximab era

利妥昔单抗时代原发性皮肤弥漫大B细胞淋巴瘤,腿型的治疗效果和CNS复发风险

2025-08-290
OAAI
Optimization and validation of the international metabolic prognostic index for CD19 CAR-T in large B-cell lymphoma

CD19 CAR-T在大型B细胞淋巴瘤中国际代谢预后指数的优化与验证

2025-08-260
OAAI
Humoral vaccine responses following Chimeric Antigen Receptor T-cell therapy for hematological malignancies

嵌合抗原受体T细胞疗法治疗血液系统恶性肿瘤后的体液疫苗反应

2025-07-020
OAAI
Barriers to Chimeric Antigen Receptor T-Cell Therapy

嵌合抗原受体T细胞疗法中的障碍

2025-05-150
PRE
Outcomes of patients with relapsed/refractory lymphoplasmacytic lymphoma/waldenström macroglobulinemia treated with venetoclax: a multicenter retrospective analysis

复发/难治性淋巴浆细胞样淋巴瘤/华氏巨球蛋白血症患者接受维奈克拉治疗后的结局:一项多中心回顾性分析

2025-04-150
OA
Report of Consensus Panel 5 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on the management of patients with intolerance or resistance to covalent BTK inhibitors

第十二届华氏巨球蛋白血症国际研讨会第五共识小组关于对共价BTK抑制剂不耐受或耐药患者管理的报告

2025-04-080
PREAI
Predictors and implications of renal injury after CD19 chimeric antigen receptor T-cell therapy

CD19嵌合抗原受体T细胞治疗后肾损伤的预测及意义

2024-11-211
OAAI
Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes

具有MYC,BCL2和/或BCL6重排的有限阶段高级别b细胞淋巴瘤: BCL2重排导致不良结果

2024-10-140
OAAI
Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study (JUL, 10.1038/s41591-024-02986-9, 2024)
2024-07-094
OAAI
Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study
2024-06-039
OAAI
Emapalumab as salvage therapy for adults with malignancy-associated hemophagocytic lymphohistiocytosis
2024-05-160
OAAI
Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP
2024-04-280
OAAI
Conventional and novel [18F]FDG PET/CT features as predictors of CAR-T cell therapy outcome in large B-cell lymphoma
2024-04-235
OAAI
Diffuse large B-cell lymphoma involving osseous sites: utility of response assessment by PET/CT and good long-term outcomes
2023-08-312
OAAI
Retrospective characterization of nodal marginal zone lymphoma
2023-08-244
OAAI
CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results

CD19 CAR T细胞治疗和预防性anakinra治疗复发或难治性淋巴瘤: 2期试验中期结果

2023-07-0363
PRE